Disc Medicine, Inc. (IRON) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Disc Medicine (IRON) by buying shares or fractional shares at any major broker, through a biotech ETF that holds it, or as one holding in a thematic basket. Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for serious hematologic (blood) diseases, and like most pre-revenue biotechs its share price is driven by clinical trial readouts and FDA decisions more than by sales or profits. In October 2026 its Phase 3 APOLLO trial of lead drug bitopertin met both co-primary endpoints, and the company raised about $486 million in net proceeds from a stock offering. As of November 20, 2026, IRON closed at $74.78, down about 5% year to date and about 17% over one year, with a resubmission to the FDA planned by the end of 2026 and a decision expected by mid-2027.
IRON stock price
As of 2026-11-20, Disc Medicine, Inc. (IRON) last closed at $75.14, down 18.9% over the past year. Over the past 52 weeks it has traded between $55.74 and $94.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Disc Medicine, Inc.'s investor relations page. Walnut is informational, not investment advice.
IRON key stats
At $75.14 on November 20, 2026, Disc Medicine, Inc. (IRON) has a market cap of $3.4B.
- Market cap
- $3.4B
- Price to book
- 4.8
- Beta
- 2.01
Market cap, P/E and yield are measured at the $75.14 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Disc Medicine, Inc. (IRON)?
The last two weeks for Disc Medicine, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- IRON closed at $75.14 on November 20, 2026, down 6.1% over the past five trading days (from $80.00).
- On November 19, 2026, Cantor Fitzgerald kept its Overweight rating and $170.00 target.
- On November 18, 2026, Morgan Stanley raised its target to $104.00 from $92.00 (Overweight).
- On November 9, 2026, Guggenheim started coverage at Buy, target $132.00.
Disc Medicine, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Disc Medicine, Inc. (IRON) do?
Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), selcodebart (DISC-0974, an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.
As a clinical-stage biotech, Disc Medicine generates essentially no product revenue and runs at a net loss as it funds research and clinical trials. The investment picture is therefore about pipeline probability and cash. The FDA issued a complete response letter for bitopertin in February 2026, finding existing data insufficient for accelerated approval, which pushed the company toward its Phase 3 APOLLO trial (183 patients). In October 2026 APOLLO met both co-primary endpoints: bitopertin cut whole-blood metal-free protoporphyrin IX (PPIX) by 41.4% versus placebo (p<0.0001) and added 12.2 hours of average monthly time in light without pain in month 6 (p=0.0010), and every secondary endpoint was also significant. Dizziness was the most common side effect (50% of patients, mostly mild or moderate). Disc plans to resubmit its application by the end of 2026 and expects an FDA decision by mid-2027. Other 2026 updates included positive Phase 2 RALLY-MF anemia data for selcodebart (a 56% major anemia response rate and 72% overall anemia response rate across evaluable patients) and initial RESTORE-PV Phase 2 data for DISC-3405 in September, with more data from both due at the ASH meeting in December 2026. Right around the readout Disc sold stock in an upsized offering priced at $450 million, bringing in about $486 million of net proceeds. Cash, equivalents and marketable securities were about $683 million at September 30, 2026, the net loss was about $59.5 million in the September quarter, and management now guides that cash funds its plans into 2030. At $74.78 on November 20, 2026 the stock was down about 5% year to date and about 17% over one year, but well above its pre-readout level of $56.55 in mid-October, giving a market value near $3.4 billion. Its value ultimately depends on whether these programs reach the market and sell.
What's driving Disc Medicine, Inc. (IRON)?
1. Bitopertin: APOLLO succeeded, approval is next.
Bitopertin in erythropoietic porphyrias is Disc's most advanced program and its nearest-term commercial opportunity. After the FDA's February 2026 complete response letter declined accelerated approval, the company ran the 183-patient Phase 3 APOLLO trial, and in October 2026 it met both co-primary endpoints (a 41.4% reduction in PPIX and 12.2 more hours a month in light without pain, versus placebo) plus all secondary endpoints. An earlier Type A meeting aligned with the FDA that a successful APOLLO can support the CRL response and potentially a traditional approval. Disc plans to resubmit by the end of 2026 and expects an FDA decision by mid-2027; analysts tracked by Yahoo pencil in about $44 million of revenue in 2027, the first sales the company would book.
2. Selcodebart (DISC-0974) in anemia of myelofibrosis.
Selcodebart, formerly DISC-0974, is an anti-hemojuvelin antibody targeting anemia in myelofibrosis, a large unmet need. Phase 2 RALLY-MF data showed a 56% major anemia response rate and a 72% overall anemia response rate across evaluable patients, including patients on JAK inhibitors, with generally favorable tolerability. Updated RALLY-MF data will be presented at the ASH annual meeting in December 2026, and an End of Phase 2 meeting with the FDA is expected in the fourth quarter, with plans for a registrational trial to be announced by year-end. A Phase 2 study in inflammatory bowel disease is expected to report initial data in 2027.
3. Broader hematology pipeline optionality.
DISC-3405, an anti-TMPRSS6 antibody, is being studied in polycythemia vera (Phase 2 RESTORE-PV, fully enrolled, with initial results presented at the SOHO meeting in September 2026 and updated data including a weekly-dosing cohort due at ASH in December) and sickle cell disease (Phase 1b, with initial data also due at ASH), with early data showing increased hepcidin and reduced serum iron. A pipeline spanning multiple mechanisms and blood disorders gives Disc several independent shots on goal. Each additional program adds potential value but also adds cost and execution risk before any of them are proven.
4. Strong balance sheet and cash runway.
Disc reported about $683 million of cash, equivalents and marketable securities at September 30, 2026 against about $61 million of debt, and in October it added about $486 million of net proceeds from a public stock offering. The net loss ran about $59.5 million in the September quarter (about $243 million over the trailing year), and management now guides that cash funds operations, capital spending and debt service into 2030, which covers the resubmission, an FDA decision and an initial bitopertin launch without immediate financing pressure. The October raise diluted holders, but a funded balance sheet reduces the risk of a forced raise at a weak share price later.
What are the risks to Disc Medicine, Inc. (IRON)?
Disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail. APOLLO's success lowers but does not remove regulatory risk: the February 2026 complete response letter for bitopertin is a reminder that the FDA can ask for more, and a decision is not expected until around mid-2027. Selcodebart and DISC-3405 are still in Phase 2 or earlier, and disappointing data at ASH in December 2026 or at later readouts could weigh on the stock. Dizziness affected half of APOLLO patients, which could matter for labeling and uptake. The shares traded at $74.78 on November 20, 2026, still well below their 52-week high of $99.50. The company burns roughly $60 million a quarter, and the October 2026 offering of about $486 million net shows it will sell stock when needed, which dilutes existing shareholders. Even successful drugs face commercial risk in small rare-disease markets, competition from established therapies, manufacturing and reimbursement hurdles, and the concentration risk of a pipeline built around a few key programs. The stock is highly volatile and pays no dividend.
What is the Disc Medicine, Inc. (IRON) forecast?
13 analysts publish price targets on IRON, averaging $127.69 as of November 2026, or +69.9% against the $75.14 share price on November 20, 2026. The published targets run from $104.00 to $170.00, a moderate spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full IRON forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is IRON a buy or a sell?
We give no verdict on Disc Medicine, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Bitopertin: APOLLO succeeded, approval is next. Bitopertin in erythropoietic porphyrias is Disc's most advanced program and its nearest-term commercial opportunity. The most optimistic published target, $170.00, assumes this works close to its best case.
The case against. Disc Medicine is a clinical-stage company with no product revenue, so it is not profitable and its value rests on programs that can still fail. The most pessimistic target, $104.00, is roughly what IRON is worth if this bites instead.
Read the full bull and bear case on IRON, including what would have to change to break either one. Walnut is not an investment adviser.
Has Disc Medicine, Inc. (IRON) split its stock?
Yes. Disc Medicine, Inc. (IRON) has had one share split in the last 10 years:
- 1:30 on December 30, 2022, so every share held became 0.03333333333333333 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of IRON the day before the 1:30 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Disc Medicine, Inc. (IRON) valued?
Market cap, P/E and dividend yield at today's price are in the IRON key stats above. The business figures below come from Disc Medicine, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$0 (pre-revenue, clinical stage); ~$44 million expected for 2027
- Net loss (TTM): ~$243 million (EPS ~-$6.34)
- Q3 2026 net loss: ~$59.5 million; EPS -$1.53 vs -$1.71 estimate
- Cash and investments (Sept. 30, 2026): ~$683 million, plus ~$486 million net raised in October; ~$61 million debt
- Cash runway: Guided into 2030
- Dividend: None
As of November 2026: As a clinical-stage biotech, Disc has no product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its September cash plus the October raise comes to roughly $1.2 billion, about a third of its market value near $3.4 billion, so a big share of the price is the balance sheet plus the value the market assigns to a bitopertin approval and to selcodebart and DISC-3405. The mean analyst target among 13 tracked by Yahoo was about $128 in November 2026, with Guggenheim starting coverage at $132, and the FDA resubmission and mid-2027 decision are the next major events.
Who competes with Disc Medicine, Inc. (IRON)?
Rare hematology and iron-pathway biotechs
Companies developing therapies for anemias and iron-metabolism disorders, such as Agios Pharmaceuticals (mitapivat/PYRUKYND), Keros Therapeutics, and Protagonist Therapeutics. They compete with Disc for the same patient populations, clinical talent, and investor attention in hematology.
Myelofibrosis and blood-cancer players
Firms addressing myelofibrosis and its anemia, including GSK (momelotinib/Ojjaara), Incyte (ruxolitinib/Jakafi), and Geron. DISC-0974 targets anemia in these patients, so approved and investigational therapies in this space are direct commercial competition.
Porphyria and rare-disease specialists
Companies with approved or developing treatments touching porphyrias and related rare diseases, such as Alnylam Pharmaceuticals (givosiran/Givlaari) and Recordati (afamelanotide/Scenesse for EPP). Bitopertin would enter markets where some of these therapies are already established.
What stocks are similar to Disc Medicine, Inc. (IRON)?
Other names that sit close to IRON: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Disc Medicine, Inc. (IRON)
There are three common ways to get IRON exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IRON sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where IRON fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Disc Medicine, Inc. (IRON)
Disc Medicine is a clinical-stage hematology biotech with no product revenue yet, a large cash cushion (about $683 million at September 30, 2026 before an October offering that added about $486 million, guided to last into 2030), and a value that hinges on regulatory and trial outcomes across its lead programs. The APOLLO Phase 3 success removed the biggest near-term binary risk for bitopertin, so the next tests are the FDA resubmission planned by year-end 2026 and an approval decision expected by mid-2027. It tends to behave as a high-volatility, event-driven biotech stock: large swings around data readouts and FDA milestones, with no dividend and meaningful risk of loss if key programs fail.
More on Disc Medicine, Inc. (IRON)
Whether IRON is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IRON a buy or a sell?, and where the stock could go from here in the IRON stock forecast.
For income investors, whether IRON pays a dividend and how the payout looks is covered in does IRON pay a dividend? And to weigh IRON against a peer, read the full side-by-side comparisons: IRON vs AGIO and IRON vs PTGX.
Wondering how IRON fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Disc Medicine, Inc.
Ask Walnut's AI anything about IRON and see how it fits what you own.
FAQ
What does Disc Medicine (IRON) do?
+
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for serious blood (hematologic) diseases. Its programs target the pathways behind red blood cell formation and iron balance, including therapies for erythropoietic porphyrias and anemia of myelofibrosis.
Is IRON profitable?
+
No. As a clinical-stage biotech, Disc has no product revenue and runs at a net loss (about $243 million over the trailing year to September 2026, and about $59.5 million in the September quarter) as it funds research and clinical trials. Profitability would depend on getting drugs approved and successfully launched; analysts expect the first revenue in 2027 if bitopertin is approved.
Does IRON pay a dividend?
+
No. Disc Medicine does not pay a dividend. Like most pre-revenue biotechs, it reinvests all of its capital into research and development instead of returning cash to shareholders.
What are Disc Medicine's lead drug programs?
+
The lead programs are bitopertin for erythropoietic porphyrias (EPP and XLP), selcodebart (DISC-0974) for anemia of myelofibrosis, and DISC-3405 for conditions such as polycythemia vera and sickle cell disease. Bitopertin is the most advanced program: its Phase 3 APOLLO trial met both co-primary endpoints in October 2026, and Disc plans to resubmit it to the FDA by the end of 2026.
What happened with bitopertin and the FDA?
+
In February 2026 the FDA issued a complete response letter, finding the existing data insufficient to support accelerated approval. Disc then ran the Phase 3 APOLLO trial (183 patients), which in October 2026 met both co-primary endpoints and all secondary endpoints. The FDA had agreed in a Type A meeting that a successful APOLLO can serve as the basis for the CRL response, and Disc plans to resubmit by the end of 2026 and expects a decision by mid-2027.
How much cash does Disc Medicine have?
+
The company reported about $683 million in cash, equivalents and marketable securities at September 30, 2026, against about $61 million of debt, and in October 2026 it raised about $486 million of net proceeds in a public stock offering. With quarterly net losses near $60 million, management says that funds its operating plans into 2030.
Why is IRON stock so volatile?
+
Its value depends on binary events like clinical trial readouts and FDA decisions more than on sales or profits. A single positive or negative result can cause large price swings, which is typical for clinical-stage biotech stocks: the shares rose from $56.55 in mid-October 2026 to $74.78 by November 20 after the APOLLO results.
How has IRON stock performed in 2026?
+
As of November 20, 2026, IRON closed at $74.78, down about 5% year to date and about 17% over one year, though well above its mid-October level before the APOLLO readout. Its 52-week range was $40.00-99.50, and its market value was about $3.4 billion.
How did Disc Medicine do in its latest quarter?
+
For the third quarter of 2026, Disc reported a net loss of about $59.5 million, or $1.53 a share, narrower than the -$1.71 estimate, with R&D expense of about $44.1 million and SG&A of about $20.1 million. It ended September with about $683 million of cash and investments, before the October offering, and extended its cash runway guidance into 2030.
What did the APOLLO Phase 3 trial show?
+
In patients with erythropoietic protoporphyria, bitopertin reduced whole-blood metal-free PPIX by 41.4% versus placebo (p<0.0001) and increased average monthly time in light without pain by 12.2 hours in month 6 (p=0.0010), meeting both co-primary endpoints. All secondary endpoints were also significant. Dizziness was the most common adverse event, in 50% of patients, mostly mild or moderate, with no events above Grade 3.
How can I invest in IRON?
+
You can buy Disc Medicine shares or fractional shares through any major brokerage, hold it via a biotech or small-cap ETF that includes it, or track it as one holding in a thematic basket. Walnut is not an investment adviser, and biotech stocks carry meaningful risk of loss.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Disc Medicine, Inc.'s investor relations page or your broker before making investment decisions.